Trial against hyperlipidemia patients with high risks to investigate the effect on small dense LDL-C and IDL by using middle dose Rosuvastatin in Saitama.
Phase of Trial: Phase II
Latest Information Update: 29 Sep 2017
At a glance
- Drugs Rosuvastatin (Primary)
- Indications Hyperlipidaemia
- Focus Therapeutic Use
- Acronyms PIONEER-Saitama
- 27 Sep 2017 Planned number of patients changed from 90 to 200.
- 23 Jan 2014 Status changed to completed as per University Hospital Medical Information Network - Japan.
- 18 Sep 2012 New trial record